<!DOCTYPE html>
<html lang="en">
<head><!-- Google Tag Manager --> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-N4XZHNC');</script> <!-- End Google Tag Manager -->

<title>Prostate Cancer Treatment Options</title>
  <meta charset="utf-8">
  
  <link href="urology2.css" rel="stylesheet">

<meta name="keywords" content="prostate cancer, treatment, algorithm" >
<meta name="description" content="Prostate cancer treatment options, from the online textbook of urology by D. Manski" >
<meta name="author" content="Dr. med. Dirk Manski" >
<meta name="copyright" content="Dirk Manski" >
<meta name="robots" content="index">
<meta name="robots" content="follow">
<meta name="viewport" content="width=device-width, initial-scale=1">
 </head>

<body><!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-N4XZHNC" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
<header>
    <a class="ribbon" tabindex="-1" title="back to start!" href="https://www.urology-textbook.com/index.html">
	   <p><span style="font-size: 1.2em;">Urology Textbook</span><br>
       
       <span style="font-size: 0.8em;">Clinical Essentials</span>
       <br>
       <span style="font-size: 0.6em;">By Dirk Manski, MD</span></p>
    </a>  
</header>
<main> 
<article>
<nav role="navigation">
<div id="menuToggle">
<input type="checkbox" id="menuCheckbox" />
     <span></span>
    <span></span>
    <span></span>
<ul id="menu">
<li>
        <a href="https://www.urology-textbook.com/anatomy.html">
          <label for="menuCheckbox" onclick="this.parentNode.click();">Anatomy</label>
        </a>
      </li>
<li><a href="https://www.urology-textbook.com/signs-and-symptoms.html">Signs and Symptoms</a></li>
<li><a href="https://www.urology-textbook.com/examinations.html">Examinations</a></li>
<li><a href="https://www.urology-textbook.com/surgical-management.html">Surgical Management</a></li>
<li><a href="https://www.urology-textbook.com/pharmacology.html">Pharmacology</a></li>
<li><a href="https://www.urology-textbook.com/kidneys.html">Kidneys</a></li>
<li><a href="https://www.urology-textbook.com/ureters.html">Ureters</a></li>
<li><a href="https://www.urology-textbook.com/bladder.html">Bladder</a></li>
<li><a href="https://www.urology-textbook.com/prostate.html">Prostate</a></li>
<li><a href="https://www.urology-textbook.com/urethra.html">Urethra</a></li>
<li><a href="https://www.urology-textbook.com/penis.html">Penis</a></li>
<li><a href="https://www.urology-textbook.com/testes.html">Testes</a></li>
<li><a href="https://www.urology-textbook.com/adrenal-glands.html">Adrenal Glands</a></li>
<li><a href="https://www.urology-textbook.com/common-diseases.html">Common Diseases</a></li>
<li><a href="https://www.urology-textbook.com/urologic-surgery.html">Urologic Surgery</a></li>
<li><a href="https://www.urology-textbook.com/index-urology.html">Index</a></li>
<li><a href="https://www.urology-textbook.com/medical-abbreviations.html">Abbreviations</a></li>
<li><a href="https://www.urology-textbook.com/urology-news.html">News</a></li>
<li><a href="https://www.urology-textbook.com/links.html">Links</a></li>
</ul>



 
</div>
</nav>

<p id="brotkrumen">&nbsp;You are here: <a href="https://www.urology-textbook.com/index.html">Urology Textbook</a> &gt; <a href="https://www.urology-textbook.com/prostate.html">Prostate</a> &gt; <a href="https://www.urology-textbook.com/prostate-cancer.html">Prostate cancer</a> &gt; Treatment options</p>
<h1>Prostate Cancer Treatment Options</h1><ul title="prostate cancer sections">
<li><a href="https://www.urology-textbook.com/prostate-cancer.html">Prostate cancer: Epidemiology and etiology </a> </li>

<li><a href="https://www.urology-textbook.com/prostate-cancer-pathology.html">Prostate cancer: Pathology</a> </li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-signs-and-symptoms.html">Prostate cancer: Signs and symptoms</a> </li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-screening.html">Prostate cancer: Screening</a> </li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-staging.html">Prostate cancer: Staging</a> </li>
<li><strong>Prostate cancer: Treatment options</strong></li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-active-surveillance.html">Prostate cancer: Active surveillance</a></li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-prostatectomy.html">Prostate cancer: Prostatectomy</a></li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-radiation-therapy.html">Prostate cancer: Radiation therapy</a> </li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-brachytherapy.html">Prostate cancer: Brachytherapy</a></li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-turp-hifu.html">Prostate cancer: TURP and experimental treatment options </a></li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-hormonal-therapy.html">Prostate cancer: androgen deprivation therapy of advanced prostate cancer</a></li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-castration-resistant.html">Prostate cancer: Treatment of castration-resistant prostate cancer</a></li>
</ul>
<br>
 
<p>Guidelines and review literature: (<a href="https://uroweb.org/guidelines/prostate-cancer/">EAU Guidelines Prostate Cancer</a>) (<a href="https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/">S3-Leitlinie Prostatakarzinom</a>) (Walsh-Campbell Urology).</p>

<h2>Treatment Algorithm for Prostate Cancer Depending On Clinical Risk and Life Expectancy</h2>

<p>For the clinical risk stratification, see table <a href="https://www.urology-textbook.com/prostate-cancer-staging.html#pca_risiko_damico">D'Amico risk stratification of prostate cancer</a>.</p><h3>Localized Prostate Cancer</h3>

<h4>Low-Risk Prostate Cancer (<a href="https://www.urology-textbook.com/psa-test.html">PSA &lt;10 ng/ml</a> <i>and</i> Gleason Score&nbsp;&leq;6): </h4>
    <p>The cancer-specific mortality is low within 10–15 years; randomized trials did not show a significant differences between observation and <a href="https://www.urology-textbook.com/retropubic-radical-prostatectomy.html">radical prostatectomy</a> after ten years (Wilt et al., 2012) (Hamdy et al., 2016). After 20 years, the PIVOT trial showed 5% survival benefit for patients after radical prostatectomy vs. observation, but the risk of androgen deprivation therapy (22% vs. 44%) was significantly reduced by surgery (Wilt et al., 2017). </p>

<h5>Life Expectancy Over 15 Years:</h5>
<p><a href="prostate-cancer-active-surveillance.html">Active surveillance</a> is a treatment option for patients who wish deferred therapy to avoid side effects. If treatment is desired or if patients progress under active surveillance, patients can choose between radical prostatectomy, <a href="prostate-cancer-radiation-therapy.html">external beam radiation therapy</a>, or <a href="prostate-cancer-brachytherapy.html">brachytherapy</a>.  </p>

<h5>Life Expectancy Below 15 Years: </h5>
<p>Active surveillance is the therapy of choice. If patients progress under active surveillance, curative radiation therapy or radical prostatectomy are possible. As an alternative to active treatment with immediate side effects, watchful waiting for <a href="prostate-cancer-hormonal-therapy.html">metastatic disease and start of ADT</a> is also an option.</p>

<h4>Intermediate and High-Risk Prostate Cancer (PSA &gt; 10 ng/ml <i>or</i> Gleason Score&nbsp;&geq;7): </h4>
<p>There is a relevant risk within ten years of progressing to metastatic disease or dying from prostate cancer within 15 years. Curative treatment is necessary for patients with a life expectancy of over 5&ndash;10 years (depending on the co-morbidities). </p>

<h5>Life expectancy Over 10 years: </h5>
<p>Radical prostatectomy is the treatment of choice. Patients with R1 resection may need adjuvant radiotherapy, and patients with lymph node metastases may need adjuvant androgen deprivation therapy. As an alternative, curative radiotherapy with adjuvant androgen deprivation therapy is an option. For poorly differentiated tumors, radical prostatectomy has better results in retrospective comparative series than radiotherapy. </p>

<h5>Life Expectancy Below 10 Years: </h5>
<p>Curative radiotherapy with adjuvant androgen deprivation therapy is treatment of choice. For patients with subvesical obstruction, radical prostatectomy should be preferred. </p>

<h5>Life Expectancy Below 5 Years: </h5>
<p>TURP for patients with subvesical obstruction. A curative therapy is unnecessary. ADT is indicated for local or systemic progression.  </p>

<h4>Metastatic Prostate Cancer:</h4>
<p>Androgen deprivation therapy is the initial treatment of choice. Depending on clinical risk or progression, <a href="prostate-cancer-castration-resistant#PCA_M1_english">numerous additional or sequential therapy options are available</a>. In oligometastatic patients with high life expectancy, local therapy (percutaneous radiotherapy or radical prostatectomy) and radiation of the metastases may be considered in addition to androgen deprivation therapy. Important is the palliation of symptoms in patients with systemic progression: pain therapy, bisphosphonates, denosumab, and radiotherapy of painful bone metastases. </p>

<br>
<br>

<div id="ad-footer">
<!-- ad-footer -->
<ins class="adsbygoogle"
     style="display:inline-block;width:500px;height:250px"
     data-ad-client="ca-pub-9284927104423861"
     data-ad-slot="8746163219"></ins>
 <script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>
</div>
<br><table id="navigation_unten">
<tr>
 
<td><a href="https://www.urology-textbook.com/prostate-cancer-staging.html">Prostate cancer staging</a></td>
<td><a class="nav4" href="https://www.urology-textbook.com/index-urology.html">Index</a></td>
<td><a class="nav3" href="https://www.urology-textbook.com/prostate-cancer-active-surveillance.html">Prostate cancer active surveillance</a></td>
 
</tr>
</table>

<br>
<br>
Index: <a href="https://www.urology-textbook.com/index-urology-a.html">1&ndash;9</a> <a href="https://www.urology-textbook.com/index-urology-a.html">A</a> <a href="https://www.urology-textbook.com/index-urology-b.html">B</a> <a href="https://www.urology-textbook.com/index-urology-c.html">C</a> <a href="https://www.urology-textbook.com/index-urology-d.html">D</a> <a href="https://www.urology-textbook.com/index-urology-e.html">E</a> <a href="https://www.urology-textbook.com/index-urology-f.html">F</a> <a href="https://www.urology-textbook.com/index-urology-g.html">G</a> <a href="https://www.urology-textbook.com/index-urology-h.html">H</a> <a href="https://www.urology-textbook.com/index-urology-i.html">I</a> <a href="https://www.urology-textbook.com/index-urology-j.html">J</a> <a href="https://www.urology-textbook.com/index-urology-k.html">K</a> <a href="https://www.urology-textbook.com/index-urology-l.html">L</a> <a href="https://www.urology-textbook.com/index-urology-m.html">M</a> <a href="https://www.urology-textbook.com/index-urology-n.html">N</a> <a href="https://www.urology-textbook.com/index-urology-o.html">O</a> <a href="https://www.urology-textbook.com/index-urology-p.html">P</a> <a href="https://www.urology-textbook.com/index-urology-q.html">Q</a> <a href="https://www.urology-textbook.com/index-urology-r.html">R</a> <a href="https://www.urology-textbook.com/index-urology-s.html">S</a> <a href="https://www.urology-textbook.com/index-urology-t.html">T</a> <a href="https://www.urology-textbook.com/index-urology-u.html">U</a> <a href="https://www.urology-textbook.com/index-urology-v.html">V</a> <a href="https://www.urology-textbook.com/index-urology-w.html">W</a> <a href="https://www.urology-textbook.com/index-urology-xyz.html">X Y Z</a> 

<br>
<br>
<h3>References</h3>

<a NAME="Albertsen1998">
Albertsen u.a. 1998 A<SMALL>LBERTSEN</SMALL>, P.&nbsp;C.&nbsp;; H<SMALL>ANLEY</SMALL>,
  J.&nbsp;A.&nbsp;; G<SMALL>LEASON</SMALL>, D.&nbsp;F.&nbsp;; B<SMALL>ARRY</SMALL>, M.&nbsp;J.:
    </a>
 Competing risk analysis of men aged 55 to 74 years at diagnosis
  managed conservatively for clinically localized prostate cancer.
<br> In: <I>Jama</I>
    <br> 280 (1998), Nr.&nbsp;11, S.&nbsp;975&ndash;80


<p>
<a NAME="Dall'Era2008">
M.&nbsp;A. Dall'Era, M.&nbsp;R. Cooperberg, J.&nbsp;M. Chan, B.&nbsp;J. Davies, P.&nbsp;C. Albertsen,
  L.&nbsp;H. Klotz, C.&nbsp;A. Warlick, L.&nbsp;Holmberg, D.&nbsp;E. Bailey, M.&nbsp;E. Wallace, P.&nbsp;W.
  Kantoff, and P.&nbsp;R. Carroll.
    </a>
 Active surveillance for early-stage prostate cancer: review of the
  current literature.
<br> <SPAN  CLASS="textit">Cancer</SPAN>, 112 (8): 1650&ndash;1659, Apr 2008.
<br> doi: rm10.1002/cncr.23373.
    <br> URL <TT><a href="https://dx.doi.org/10.1002/cncr.23373">https://dx.doi.org/10.1002/cncr.23373</a></TT>.
  <br>
  <br>
    
    <p>
Fleshner, N. E.; Lucia, M. S.; Egerdie, B.; Aaron, L.; 
    Eure, G.; Nandy, I.; Black, L. &amp; Rittmaster, R. S.
    <a href="https://www.urology-textbook.com/dutasteride.html">Dutasteride</a> in 
    localised prostate cancer management: the REDEEM randomised, double-blind, 
    placebo-controlled trial.<br><em>Lancet, </em><b>2012</b><i>, 379</i>, 
    1103-1111.
    <br>
    <br>
    Hamdy, F. C.; Donovan, J. L.; Lane, J. A.; Mason, 
    M.; Metcalfe, C.; Holding, P.; Davis, M.; Peters, T. J.; Turner, E. L.; 
    Martin, R. M.; Oxley, J.; Robinson, M.; Staffurth, J.; Walsh, E.; Bollina, 
    P.; Catto, J.; Doble, A.; Doherty, A.; Gillatt, D.; Kockelbergh, R.; 
    Kynaston, H.; Paul, A.; Powell, P.; Prescott, S.; Rosario, D. J.; Rowe, 
    E.; Neal, D. E. &amp; Group, P. S.
    10-Year Outcomes after Monitoring, 
    Surgery, or Radiotherapy for Localized Prostate Cancer.<br><em>The New 
    England journal of medicine, </em><b>2016</b><i>, 375</i>, 1415-1424</p>

   <p> <a NAME="EAU-Guidelines"></a>N. Mottet (Chair), J. Bellmunt, E. Briers (Patient Representative), R.C.N. van den Bergh (Guidelines Associate),
        M. Bolla, N.J. van Casteren (Guidelines Associate), P. Cornford, S. Culine, S. Joniau, T. Lam, M.D. Mason, V. Matveev, H. van der Poel, T.H. van der Kwast, O. Rouvière, T. Wiegel
        Guidelines on Prostate Cancer of the European Association of Urology (EAU), <a href="https://uroweb.org/guidelines/prostate-cancer/">https://uroweb.org/guidelines/prostate-cancer/</a>.</p>

<br>
<br>
    <a name="s3-leitlinie"></a>Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe,
AWMF): 
Interdisziplin&auml;re Leitlinie der Qualit&auml;t S3 zur Fr&uuml;herkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom
<br>
<br>

Leyh-Bannurah, S.-R.; Gazdovich, S.; Bud&#228;us, L.; 
    Zaffuto, E.; Briganti, A.; Abdollah, F.; Montorsi, F.; Schiffmann, J.; 
    Menon, M.; Shariat, S. F.; Fisch, M.; Chun, F.; Steuber, T.; Huland, H.; 
    Graefen, M. &amp; Karakiewicz, P. I.
    Local Therapy Improves Survival in 
    Metastatic Prostate Cancer.<br><em>European urology, </em><b>2017</b><i>, 
    72</i>, 118-124
    
<br>
<br>
Parker, C. C.; James, N. D.; Brawley, C. D.; 
    Clarke, N. W.; Hoyle, A. P.; Ali, A.; Ritchie, A. W. S.; Attard, G.; 
    Chowdhury, S.; Cross, W.; Dearnaley, D. P.; Gillessen, S.; Gilson, C.; 
    Jones, R. J.; Langley, R. E.; Malik, Z. I.; Mason, M. D.; Matheson, D.; 
    Millman, R.; Russell, J. M.; Thalmann, G. N.; Amos, C. L.; Alonzi, R.; 
    Bahl, A.; Birtle, A.; Din, O.; Douis, H.; Eswar, C.; Gale, J.; Gannon, M. 
    R.; Jonnada, S.; Khaksar, S.; Lester, J. F.; O'Sullivan, J. M.; Parikh, O. 
    A.; Pedley, I. D.; Pudney, D. M.; Sheehan, D. J.; Srihari, N. N.; Tran, A. 
    T. H.; Parmar, M. K. B.; Sydes, M. R. &amp; for Advanced or Metastatic 
    Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators, S. 
    T.
    Radiotherapy to the primary tumour for newly diagnosed, metastatic 
    prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.<br><em>Lancet, 
    </em><b>2018</b><i>, 392</i>, 2353-2366.
    <br>
    <br>

Wein, A. J.; Kavoussi, L. R.; Partin, A. P. &amp; Peters, C. A.
Campbell-Walsh Urology<br><em>. Elsevier, </em><b>2015</b>. ISBN 978-1455775675.
<br>
<br>
Studer, U. E.; Collette, L.; Whelan, P.; Albrecht, W.; 
    Casselman, J.; de Reijke, T.; Knönagel, H.; Loidl, W.; Isorna, S.; 
    Sundaram, S. K.; Debois, M. &amp; , E. O. R. T. C. G. G.
    Using PSA to 
    guide timing of androgen deprivation in patients with T0-4 N0-2 M0 
    prostate cancer not suitable for local curative treatment (EORTC 30891).<br><em>Eur 
    Urol, </em><b>2008</b><i>, 53</i>, 941-949.

<br>
<br>

Tosoian, J. J.; Trock, B. J.; Landis, P.; Feng, Z.; 
    Epstein, J. I.; Partin, A. W.; Walsh, P. C. &amp; Carter, H. B.
    Active 
    surveillance program for prostate cancer: an update of the Johns Hopkins 
    experience.<br><em>J Clin Oncol, </em><b>2011</b><i>, 29</i>, 2185-2190.
    <br>
    <br>
    
    Wilt, T. J.; Brawer, M. K.; Jones, K. M.; Barry, M. J.; 
    Aronson, W. J.; Fox, S.; Gingrich, J. R.; Wei, J. T.; Gilhooly, P.; Grob, 
    B. M.; Nsouli, I.; Iyer, P.; Cartagena, R.; Snider, G.; Roehrborn, C.; 
    Sharifi, R.; Blank, W.; Pandya, P.; Andriole, G. L.; Culkin, D.; Wheeler, 
    T. &amp; PIVOT Study Group
    Radical prostatectomy versus observation for localized 
    prostate cancer.<br><b>2012</b><i>, 367</i>, 203-213.

<br>
<br>
Wilt, T. J.; Jones, K. M.; Barry, M. J.; Andriole, 
    G. L.; Culkin, D.; Wheeler, T.; Aronson, W. J. &amp; Brawer, M. K.
    Follow-up 
    of Prostatectomy versus Observation for Early Prostate Cancer.<br><em>The 
    New England journal of medicine, </em><b>2017</b><i>, 377</i>, 132-142

<br>
<br>
<p><img src="https://images0.urology-textbook.com/deutsch.gif">&nbsp; Deutsche Version: <a href="https://www.urologielehrbuch.de/prostatakarzinom-leitlinie-aktive-ueberwachung.html">Leitlinien: Therapie Optionen des Prostatakarzinoms</a></p>    

<h3>Urology-Textbook.com – Choose the Ad-Free, Professional Resource</h3>
<p>This website is designed for physicians and medical professionals. It presents diseases of the genital organs through detailed text and images. Some content may not be suitable for children or sensitive readers. Many illustrations are available exclusively to Steady members. Are you a physician and interested in supporting this project? <a href="https://steady.page/de/urology/about">Join Steady to unlock full access</a> to all images and enjoy an ad-free experience. Try it free for 7 days&mdash;no obligation. </p>

<p><strong>New release:</strong> The first edition of the Urology Textbook as an e-book&mdash;ideal for offline reading and quick reference. With over 1300 pages and hundreds of illustrations, it’s the perfect companion for residents and medical students. After your 7-day trial has ended, you will receive a download link for your exclusive e-book.</p>
</article>
</main>
<footer class="grid">
    <ul id="footer-nav">
    		<li>Copyright by Dr. med. Dirk Manski </li>
		<li><a href="https://www.urology-textbook.com/privacy-policy.html">Privacy policy</a></li>
		<li><a href="https://www.urology-textbook.com/disclaimer.html">Disclaimer</a></li>
	</ul>
	<a class="steady-login-button" data-size="medium" data-language="en" style="display: none;"></a>
</footer>
</body>
</html>
